Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. (BEAM) is a pioneering biotechnology company developing precision genetic medicines through its innovative base editing platform. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments in gene editing technology.
Investors and researchers will find curated press releases covering therapeutic advancements, financial disclosures, and scientific partnerships. Our collection includes updates on BEAM's hematology programs, in vivo editing initiatives, and manufacturing capabilities - all essential for understanding the company's position in genetic medicine.
Key content categories include clinical trial progress for sickle cell disease therapies, intellectual property developments in base editing, and strategic collaborations advancing CRISPR-based treatments. Each update is carefully verified to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for direct access to Beam Therapeutics' latest milestones in creating single-edit genetic therapies. Check regularly for authoritative updates on one of biotechnology's most promising precision medicine platforms.
Beam Therapeutics has named BEAM-201 as a development candidate for T-cell acute lymphoblastic leukemia (T-ALL). This innovative allogeneic CAR-T therapy features simultaneous edits to four genes, achieving 96-99% on-target editing. Preclinical results show strong dose-dependent tumor control in mouse models. BEAM-201 is produced in a GMP-compliant process, utilizing T cells from healthy donors, making it an 'off-the-shelf' treatment option. The therapy addresses a severe condition, with a five-year survival rate of under 25%.
Beam Therapeutics (Nasdaq: BEAM) announced the participation of CEO John Evans in a fireside chat at the Chardan Virtual 4th Annual Genetic Medicines Conference on October 5, 2020, at 8:00 a.m. ET. The event will be accessible via a live webcast on the investor section of the company’s website, www.beamtx.com, and will be archived for 60 days post-event.
Beam Therapeutics specializes in precision genetic medicines utilizing base editing technologies to develop targeted genomic therapies, positioning itself as a leader in the biotech sector.
Beam Therapeutics Inc. (Nasdaq: BEAM) has announced the pricing of its public offering, aiming to sell 5,000,000 shares at $23.50 each. The company expects gross proceeds of approximately $117.5 million, excluding underwriter options for an additional 750,000 shares. This offering is set to close on October 5, 2020, pending customary conditions. J.P. Morgan, Jefferies, and Barclays are the joint book-running managers, with Wedbush PacGrow as the lead manager. The registration statement for the shares was effective as of September 30, 2020.
Beam Therapeutics (Nasdaq: BEAM) announced a proposed public offering of 4,500,000 shares of its common stock, with an option for underwriters to purchase an additional 675,000 shares. The offering will be managed by J.P. Morgan, Jefferies, and Barclays, with Wedbush PacGrow as the lead manager. A registration statement has been filed with the SEC, but it has not yet been declared effective. Investors are advised to review the prospectus for detailed information before investing. The company focuses on precision genetic medicines through base-editing technology.
Beam Therapeutics (Nasdaq: BEAM) announced a proposed public offering of 4,500,000 shares of its common stock. The company will offer all the shares, with an option for underwriters to purchase an additional 675,000 shares. J.P. Morgan, Jefferies, and Barclays are the joint book-running managers. The registration statement has been filed with the SEC but is not yet effective. Investors are advised to review the preliminary prospectus for more details. This offering aims to raise capital to support Beam’s precision genetic medicine initiatives through base editing.
Beam Therapeutics has named BEAM-101 and BEAM-102 as its first development candidates for treating sickle cell disease, leveraging innovative base editing technologies. The company is establishing a 100,000 sq. ft. manufacturing facility in North Carolina to enhance production capabilities. Beam ended Q2 2020 with $228 million in cash but reported a net loss of $34.2 million. The firm continues to pursue partnerships to further its genetic medicine initiatives. The company aims to file an Investigational New Drug application in 2021.
Beam Therapeutics (Nasdaq: BEAM) announced its participation in two upcoming investor conferences in August 2020. The company will be featured in the William Blair Biotech Focus Conference on August 6 at 1:00 p.m. ET, discussing 'Gene Editing and Gene Therapy in 2030.' Additionally, it will present at the Wedbush PacGrow Healthcare Virtual Conference on August 12 at 9:45 a.m. ET. Live webcasts of these events will be accessible on the investor section of Beam's website and archived for 60 days thereafter.
Beam Therapeutics (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicine, announced that CEO John Evans will present at the Jefferies 2020 Virtual Healthcare Conference on June 4, 2020, at 9:30 a.m. ET. The conference runs from June 2-4, 2020. The presentation will be available via live webcast on the company's investor website, with an archive accessible for 60 days post-event. Beam Therapeutics focuses on base editing technology, creating precise genetic modifications without double-stranded DNA breaks, aiming to provide lasting solutions for serious diseases.
Beam Therapeutics Inc. (Nasdaq: BEAM) reported significant advancements in its genetic medicine programs, showcasing a more than four-fold increase in circulating levels of functional protein for Alpha-1 Antitrypsin Deficiency. The company also demonstrated over 80% direct correction in sickle cell disease and greater than 90% editing in its fetal hemoglobin program. Financially, Beam holds $253.4 million in cash as of March 31, 2020, with R&D expenses rising to $21.5 million. The net loss for Q1 2020 was $31.7 million, or $1.03 per share, an increase from the previous year.
FAQ
What is the current stock price of Beam Therapeutics (BEAM)?
What is the market cap of Beam Therapeutics (BEAM)?
